- Home
- ARWR vs PEN Comparison
ARWR vs PEN Comparison
Compare ARWR & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | PEN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.6B |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARWR | PEN |
|---|---|---|
| Price | $59.98 | $321.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 17 |
| Target Price | $107.71 | ★ $362.54 |
| AVG Volume (30 Days) | ★ 1.7M | 390.6K |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 99.80 | ★ 1155.56 |
| EPS | N/A | ★ 2.77 |
| Revenue | $16,142,321.00 | ★ $1,403,665,000.00 |
| Revenue This Year | N/A | $14.38 |
| Revenue Next Year | N/A | $12.44 |
| P/E Ratio | ★ N/A | $114.96 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $37.06 | $225.52 |
| 52 Week High | $95.49 | $362.41 |
Technical Indicators
Market Signals| Indicator | ARWR | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 50.94 |
| Support Level | $54.93 | $321.10 |
| Resistance Level | $66.37 | $324.56 |
| Average True Range (ATR) | 2.22 | 2.41 |
| MACD | 0.91 | -0.25 |
| Stochastic Oscillator | 71.90 | 55.47 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.